AVI BioPharma’s therapeutic development programs include lead candidates for Duchenne muscular dystrophy, hemorrhagic virus infections and influenza. We are encouraged by positive results in preclinical and clinical trials.
This page was last updated on July 31, 2010.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |
| DMD - Exon 51 AVI-4658 |
|
||||
| DMD - Exon 50 AVI-5038 |
|
||||
| Ebola VIrus AVI-6002 |
|
||||
| Marburg Virus AVI-6003 |
|
||||
| Junin Virus AVI-7012 |
|
||||
| Influenza Therapy AVI-7100 |
|
||||
| Dengue Virus AVI-6006 |
|
||||
